

65LAB Application Form

Project Title		
<i>Indicative of research field and uniqueness of approach</i>		
Principal Investigator & Academic Title		
Institution & Department	E-mail	Telephone
Institutional/Departmental Administrator	E-mail	Telephone
Innovation & Enterprise Office (IEO) Representative	E-mail	Telephone
Co-Investigator (1)		
<i>Only include investigators who will be funded under the proposed scope of work. If you plan to involve Investigators outside your Institution, please discuss this with the 65LAB Expert in Residence and your respective technology transfer office.</i>		
Institution & Department	E-mail	Telephone
Co-Investigator (2)*		
Institution & Department	E-mail	Telephone

**Add rows if there are more Co-Investigators*

To be completed by IEO/65LAB

Institution Project Number	65LAB Project Number	Evotec Project Number

Notes to Applicants:

- Please contact your respective IEO and the Evotec EIR to discuss your application before submission.
- All applications need to be endorsed by your respective IEO.
- For more information, please contact Dr Stephen Hess (65LAB EIR) at [Email].

PROJECT INFORMATION

PROJECT TITLE:

Indicative of research field and uniqueness of approach

A) EXECUTIVE SUMMARY

Outline of scientific rationale, therapeutic relevance and proposed goals of the project including planned start date and duration. Please provide a summary of the total budget extracted from the project plan below (max 300 words).

B) INTRODUCTION

Summary of background to the proposed research including own previous work and any supporting evidence from third parties (max 1000 words). Please include the following information:

- (i) Details of the proposed target and the mechanism of action for the target/biological pathway;*
- (ii) Evidence to support that the target/biological pathway is therapeutically relevant to disease;*
- (iii) A description of the platform technology developed by the lab, if any, that helped identify the target/biological pathway/mechanism of action; and*
- (iv) Future potential and downstream applications of the platform technology.*

Please detail the current status of the project and any relevant publications. Supporting data may be appended as an annex to this application.

C) THERAPEUTIC INDICATION(S) AND MEDICAL NEED

Brief description of therapeutic problem(s) to be solved, anticipated modality(ies), and target indication(s) or disease(s) envisaged should the results of an award give rise to a product. (max 300 words)

D) COMPETITIVE APPROACHES AND MARKET POTENTIAL

Brief overview of competition in the envisaged therapeutic space and the potential size of the market to the degree applicable, e.g. how is your approach different to what is currently being used/in development and what is the size of the applicable patient population? Please list any secondary indications, and include any routes to patient stratification and potential biomarkers associated with the target hypothesis (max 500 words).

E) ANTICIPATED FOREGROUND IP

Based on the envisaged work plan and described background IP, please provide a summary of the expected deliverables upon completion of funding. Examples include a number of chemical starting points or an antibody with a desired biological effect either in vitro or in vivo, new lines, reagents, new data, know how, methods, models, and techniques.

F) BACKGROUND IP AND THIRD-PARTY FUNDING

Please complete this section in collaboration with your respective IEO for the purposes of internal Academic/Research Institution diligence. (Please note that having an existing patent application is not a pre-requisite for a successful application):

- (i) *Has the project proposal (or part thereof) been approved by other 3rd party grant funding or is it in an application process that is pending an outcome?*
- (ii) *Has the project proposal above been approved by your respective IEO for submission to 65LAB?*
- (iii) *Is there any relevant Academic/Research Institution Background IP required to perform the work under the 65LAB application? [Background IP is IP that exists before the project begins, and includes patented IP, know-how, data, materials e.g. mouse models or reagents]. Has an invention disclosure form been submitted or is this imminent? Please work with your respective IEO to provide a list of Background IP and ancillary IP to be used to perform any of the Academic/Research Institution work packages or to which access will be needed to commercialise anticipated Foreground IP.*
- (iv) *If Background IP exists, what grants or funding awards supported its creation?*
- (v) *Are there any reach through claims to future foreground IP and/ or commercialization rights imposed by any such funding bodies?*
- (vi) *If any patent applications have been filed in relation to the Academic/Research Background IP, please specify associated expenditure incurred by the Academic/Research Institution up to the date of submission of the application to 65LAB. Please also summarize the status of the patent and its relationship to the anticipated arising IP under the 65LAB award*
- (vii) *Are you aware of any external Background IP that may be needed to carry out the project; for example a mouse model sourced from a third party, or any material under an MTA? [Where possible applications will ideally avoid use of any IP subject to 3rd party rights to avoid the need to negotiate consents which may not always be possible/feasible].*
- (viii) *Do you have any conflicts of interest that may need to be managed e.g. a consultancy advising on a competing program of work?*

G) 65LAB WORK PLAN

*Please provide a description of the individual work packages for the proposed project and where the work is expected to be performed (e.g. Academic or Research Institution lab/Evotec/ 3rd party). Where funded work will be undertaken in an Academic/Research institution lab, please provide details. Please fill in the table below in collaboration with your technology transfer office representative and Evotec. **Please prepare a Gantt chart outlining these activities.***

Please include:

- (i) *A detailed research and development plan and an associated budget, including estimated costs for Evotec FTEs, all significant reagent costs and institutional overheads for work performed at the Academic/Research institution lab;*
- (ii) *Key milestones and deliverables;*

65LAB Application No.:

- (iii) *A description of any laboratories at the Academic/Research Institution that are anticipated to perform funded activities;*
- (iv) *The activities to be performed by Evotec, the Academic/Research institution lab and/or other 3rd party labs;*
- (v) *Any relevant 3rd party license fees associated with the use of a particular technology or reagent (in relation to Background IP and/or anticipated Foreground IP) and indicate where an MTA may be required to perform the work (e.g. particular cell lines); and*
- (vi) *Anticipated future patent costs associated with Academic/Research Institution Background IP likely to be incurred during the funded project and with anticipated Foreground IP.*

Work Package	Target Milestone	Time/Duration	Responsible (Institution/Evotec)	Cost

H) PROJECT TEAM

Membership and roles and responsibilities of the Project Team

I) RISK ASSESSMENT

Brief assessment of main technical risk(s) for the proposed project and how they will be addressed

J) NEXT STEPS

If the project milestones are achieved, what are the next technical (e.g. lead optimization, preclinical studies) activities? (max 300 words).